Here’s what you should know:
1. ReShape designed the intragastric balloon system to treat obese patients with a body mass index between 30 or 40 and a related comorbid condition.
2. EnteroMedics is acquiring 2,356,729 shares of common stock, 187,772 shares of series C convertible preferred stock and $5 million in cash.
3. EnteroMedics will hold a stockholder meeting on Dec. 31 to approve the conversion of the series C stock into common stock.
4. EnteroMedics CEO and President Dan Gladney will stay in his current position. ReShape Medical will add two designees to Entero’s board of directors.
More articles on gastroenterology:
GI center to know: Phoenix Endoscopy
Award winners, new hires & more: 6 GI practices in the news
Undergoing colonoscopy ups appendicitis risk 1 week after — 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
